Ocean Biomedical Company Description
Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases in the United States.
The company’s oncology product candidates include OCX-253 anti-Chi3l1 Single-target mAb and OCX-410 anti-Chi3l1/PD-1 Bi-specific antibody for the treatment of non-small cell lung cancer; and OCX-909 anti-Chi3l1/CTLA-4 Bi-specific antibody to treat glioblastoma multiforme.
Its fibrosis product candidates consist of OCF-203 anti-Chit1 small molecule for the treatment of idiopathic pulmonary fibrosis (IPF) and hermansky-pudlak syndrome (HPS).
The company’s infectious diseases product candidates for malaria include the ODA-570 vaccine for the prevention of P.
falciparum infection; ODA-611 anti-PfGARP mAb for the treatment of Symptomatic P. falciparum infection; and ODA-579 anti-PfGARP small molecule for the treatment of Symptomatic P.
falciparum infection. It has license agreement with Elkurt, Inc. for FRG Antibody, bi-specific antibody anti-CTLA4, bispecific (FRG)x anti-PD-1 (FRGxPD-1), chit1 small molecule antifibrotic, and malaria small molecules and antibodies.
The company was founded in 2019 and is based in Providence, Rhode Island. Ocean Biomedical, Inc. is a subsidiary of Poseidon Bio, LLC.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 7 |
| CEO | M. Berrey |
Contact Details
Address: 55 Claverick Street Providence, Rhode Island 02903 United States | |
| Phone | 401 444 7375 |
| Website | oceanbiomedical.com |
Stock Details
| Ticker Symbol | OCEA |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US67644C1045 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Inderjote Kathuria M.B.A., M.D. | Chief Strategy Officer |
| Dr. Chirinjeev Baboo Kathuria M.B.A., M.D. | Founder and Executive Chairman of the Board |